ArticleParticle and fibre toxicology2023
Acute and continuous exposure of airborne fine particulate matter (PM
Article in Particle and fibre toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Chronic exposure to aerosolized Arizona test dust reduces visual acuity in mice.Toxicology reports · 2026Article
- Cellular responses of human Muller glia exposed to test dust pollution.Environmental pollution (Barking, Essex : 1987) · 2026Article
- Association between air pollutant exposure and ocular surface, anterior and middle segment and fundus eye diseases: epidemiological and mechanism evidence.Eye (London, England) · 2026Review
- Long-term exposure to fine particulate matter and its constituents is related to self-reported visual impairment among middle-aged and older adults: a longitudinal study in China.BMC public health · 2025Article
- Prevalence and associated factors of vitreoretinal interface disorders using multicolour OCT among Chinese population in Fujian eye study.Scientific reports · 2025Article
- Diesel exhaust particles disrupt blood-retina barrier integrity via TLR2 and TLR4 activation.BMB reports · 2025Article
- Pathways to the Brain: Impact of Fine Particulate Matter Components on the Central Nervous System.Antioxidants (Basel, Switzerland) · 2025Review
- The global burden and attributable risk factor analysis of age-related macular degeneration in 204 countries and territories, 1990-2021.Eye (London, England) · 2025Article
- Ozone exposure and increased risk of age-related macular degeneration: Evidence from nationwide cohort and toxicological studies.Innovation (Cambridge (Mass.)) · 2025Article
- Vulnerability characteristics and adaptation strategies of public health systems in different regions of China.Frontiers in public health · 2025Review
- Exploring association between ambient air pollution and glaucoma in China: a nationwide analysis with predictive modeling based on the China Health and Retirement Longitudinal Study.Frontiers in public health · 2025Article
- Review
- Pathological Mechanisms of Particulate Matter-Mediated Ocular Disorders: A Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe association between air pollution and retinal diseases such as age-related macular degeneration (AMD) has been demonstrated, but the pathogenic correlation is unknown. Damage to the outer blood-retinal barrier (oBRB), which consists of the retinal pigment epithelium (RPE) and choriocapillaris, is crucial in the development of fundus diseases.
objectivesTo describe the effects of airborne fine particulate matter (PM
methodsA PM
resultsAcute exposure to PM
conclusionThis study reveals oBRB pathological changes under different exposure durations, providing a valuable reference for the prevention of PM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.